These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11493772)

  • 1. Can biological markers replace cystoscopy? An update.
    van der Poel HG; Debruyne FM
    Curr Opin Urol; 2001 Sep; 11(5):503-9. PubMed ID: 11493772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
    Lokeshwar VB; Soloway MS
    J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor marker tests in bladder cancer].
    Feil G; Stenzl A
    Actas Urol Esp; 2006 Jan; 30(1):38-45. PubMed ID: 16703728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP;
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer.
    Thomas L; Leyh H; Marberger M; Bombardieri E; Bassi P; Pagano F; Pansadoro V; Sternberg CN; Boccon-Gibod L; Ravery V; Le Guludec D; Meulemans A; Conort P; Ishak L
    Clin Chem; 1999 Apr; 45(4):472-7. PubMed ID: 10102906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.
    Chautard D; Daver A; Bocquillon V; Verriele V; Colls P; Bertrand G; Soret JY
    Eur Urol; 2000 Dec; 38(6):686-90. PubMed ID: 11111185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers.
    Eissa S; Kassim S; El-Ahmady O
    Curr Opin Obstet Gynecol; 2003 Oct; 15(5):395-403. PubMed ID: 14501243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder cancer. II. Molecular aspects and diagnosis.
    Kausch I; Böhle A
    Eur Urol; 2001 May; 39(5):498-506. PubMed ID: 11464029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary markers of bladder carcinoma.
    Dey P
    Clin Chim Acta; 2004 Feb; 340(1-2):57-65. PubMed ID: 14734196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.